{"id":"doravirine-dor","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Rash"}]},"_chembl":null,"_dailymed":{"setId":"76ce1f00-28c0-4314-bd2c-d473fe3d0970","title":"PIFELTRO (DORAVIRINE) TABLET, FILM COATED [MERCK SHARP & DOHME LLC]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Doravirine binds to the non-nucleoside binding pocket of HIV-1 reverse transcriptase, inhibiting the enzyme's ability to convert viral RNA into DNA. This prevents the integration of viral genetic material into the host cell genome and stops HIV replication. It is structurally distinct from earlier NNRTIs and has activity against some drug-resistant HIV strains.","oneSentence":"Doravirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that blocks HIV reverse transcriptase to prevent viral replication.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:34:22.460Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection in treatment-naïve and treatment-experienced adults (in combination antiretroviral therapy)"}]},"trialDetails":[{"nctId":"NCT04223791","phase":"PHASE3","title":"Switch to Doravirine/Islatravir (DOR/ISL) in Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-018)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-02-18","conditions":"HIV Infection","enrollment":643},{"nctId":"NCT04375800","phase":"PHASE2","title":"Doravirine (DOR) in Human Immunodeficiency Virus (HIV)-Infected Children Aged 4 Weeks to <12 Years and <45 kg (MK-1439-066)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-02-03","conditions":"Human Immunodeficiency Virus (HIV) Infection","enrollment":84},{"nctId":"NCT07086079","phase":"PHASE1","title":"A Study of Doravirine/Islatravir in Healthy Lactating Females (MK-8591A-061)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-09-26","conditions":"Healthy","enrollment":12},{"nctId":"NCT04223778","phase":"PHASE3","title":"Safety and Efficacy of a Switch to Doravirine/Islatravir in Participants With HIV-1 (MK-8591A-017)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-02-18","conditions":"HIV Infection","enrollment":672},{"nctId":"NCT04233879","phase":"PHASE3","title":"Study of Doravirine/Islatravir (DOR/ISL 100 mg/0.75 mg) to Evaluate the Antiretroviral Activity, Safety, and Tolerability in Treatment-Naïve Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-020)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-02-28","conditions":"HIV-1 Infection","enrollment":599},{"nctId":"NCT05421806","phase":"","title":"A Cohort Study of Use of Doravirine (DOR) Based Regimens in Clinical Practice in Europe DoRavirine Europe Real World/","status":"ACTIVE_NOT_RECRUITING","sponsor":"NEAT ID Foundation","startDate":"2022-10-10","conditions":"HIV I Infection","enrollment":500},{"nctId":"NCT04776252","phase":"PHASE3","title":"Open-label, Follow-up of Doravirine/Islatravir (DOR/ISL 100 mg/0.75mg) for Participants With Human Immunodeficiency Virus-1 (HIV-1) Infection (MK-8591A-033)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-09-15","conditions":"HIV-1 Infection","enrollment":2000},{"nctId":"NCT05766501","phase":"PHASE3","title":"A Study of Doravirine/Islatravir (DOR/ISL, MK-8591A) for the Treatment of Human Immunodeficiency Virus 1 (HIV-1) Infection in Participants Who Previously Received DOR/ISL (MK-8591A-054)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-03-17","conditions":"HIV Infection","enrollment":641},{"nctId":"NCT05631093","phase":"PHASE3","title":"A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Antiretroviral Therapy (ART) (MK-8591A-051)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-02-20","conditions":"HIV-1 Infection","enrollment":553},{"nctId":"NCT05630755","phase":"PHASE3","title":"A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-052)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-02-17","conditions":"HIV-1 Infection","enrollment":514},{"nctId":"NCT06630299","phase":"PHASE3","title":"Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2024-10-08","conditions":"HIV-1-Infection","enrollment":600},{"nctId":"NCT04518228","phase":"","title":"Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-09-01","conditions":"HIV Infections, Tuberculosis","enrollment":205},{"nctId":"NCT05705349","phase":"PHASE3","title":"DOR/ISL in HIV-1 Antiretroviral Treatment-naïve Participants (MK-8591A-053)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-03-08","conditions":"HIV-1 Infection","enrollment":537},{"nctId":"NCT07075146","phase":"PHASE3","title":"DOR/TDF/3TC COmpared With BIC/FTC/TAF in ART-Naïve People Living With HIV and Overweight or Obesity","status":"RECRUITING","sponsor":"José Antonio Mata Marín","startDate":"2025-05-05","conditions":"HIV - Human Immunodeficiency Virus, Obesity, Overweight and/or Obesity","enrollment":306},{"nctId":"NCT06034938","phase":"PHASE2","title":"DOR/TDF/3TC Switch With M184V/I in People With Controlled HIV (Drive Off-Road)","status":"RECRUITING","sponsor":"University Hospital, Caen","startDate":"2024-02-08","conditions":"Hiv","enrollment":32},{"nctId":"NCT04665375","phase":"PHASE4","title":"Can INSTI-associated Weight Gain be Halted or Reversed With a Switch to Doravirine/Lamivudine/Tenofovir DF?","status":"TERMINATED","sponsor":"University Health Network, Toronto","startDate":"2021-04-26","conditions":"Hiv, Weight Gain","enrollment":4},{"nctId":"NCT04636437","phase":"PHASE4","title":"Doravirine for Obese Persons on Integrase Inhibitors and Tenofovir Alafenamide","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2021-07-27","conditions":"HIV Infections","enrollment":147},{"nctId":"NCT06774872","phase":"PHASE2","title":"Doravirine/Lamivudine (DOR/3TC) as a Maintenance ART in Comparison With Dolutegravir/Lamivudine (DTG/3TC) in PLWH Successfully","status":"RECRUITING","sponsor":"Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida","startDate":"2025-04-30","conditions":"HIV-1-infection","enrollment":408},{"nctId":"NCT04669678","phase":"PHASE4","title":"Evaluation of Pharmacokinetic Drug-drug Interactions Between Hormonal Contraceptives and Doravirine-containing ART Among Women Living With HIV in South Africa","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2021-11-17","conditions":"HIV Infections, Contraception, Drug-drug Interaction","enrollment":110},{"nctId":"NCT05924438","phase":"PHASE3","title":"A Randomised, Phase 3 Non-inferiority Study of DOR/3TC/TDF Compared to DTG/TAF/FTC in Participants Infected With HIV-1 Starting First-line Antiretroviral Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Professor Francois Venter","startDate":"2023-11-08","conditions":"HIV-1-infection","enrollment":600},{"nctId":"NCT05477407","phase":"NA","title":"Adipose Tissue After Switch to Doravirine","status":"COMPLETED","sponsor":"Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida","startDate":"2022-10-06","conditions":"HIV Infections","enrollment":22},{"nctId":"NCT04233216","phase":"PHASE3","title":"Doravirine/Islatravir (DOR/ISL) in Heavily Treatment-Experienced (HTE) Participants for Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-019)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-03-18","conditions":"HIV-1 Infection","enrollment":35},{"nctId":"NCT05289986","phase":"PHASE4","title":"The Effect on Lipid Profile of Switching to Delstrigo in HIV Positive Patients","status":"TERMINATED","sponsor":"Chelsea and Westminster NHS Foundation Trust","startDate":"2023-11-21","conditions":"Hiv","enrollment":18},{"nctId":"NCT06719570","phase":"PHASE1","title":"A Study of Doravirine and Islatravir as a Single Entity or Combination Therapy and the Effect of Food in Healthy Adult Participants (MK-8591A-055)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-01-23","conditions":"Healthy","enrollment":24},{"nctId":"NCT06037564","phase":"PHASE4","title":"B-free Multistage Trial","status":"ENROLLING_BY_INVITATION","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2023-11-13","conditions":"HIV, Drug Resistance, Drug Drug Interaction","enrollment":210},{"nctId":"NCT06602622","phase":"PHASE4","title":"Change in Body Weight and BMI in PWH with DOR/3TC/TDF Compared with INSTI","status":"RECRUITING","sponsor":"Instituto Mexicano del Seguro Social","startDate":"2024-08-14","conditions":"HIV, HIV Associate Weight Loss, HIV-1 Infection","enrollment":108},{"nctId":"NCT04295772","phase":"PHASE2","title":"Doravirine/Islatravir (DOR/ISL) in Pediatric Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are <18 Years of Age and Weigh ≥35 kg (MK-8591A-028)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-11-26","conditions":"HIV-1 Infection","enrollment":42},{"nctId":"NCT05506605","phase":"PHASE4","title":"Switch Strategy From Etravirine (ETR) to Doravirine (DOR) in Virologically-Suppressed HIV-1 Infected Adults With ETR-Resistance","status":"UNKNOWN","sponsor":"Fundacion Clinic per a la Recerca Biomédica","startDate":"2022-12-12","conditions":"HIV-1-infection","enrollment":12},{"nctId":"NCT04433780","phase":"PHASE3","title":"DORA: A Doravirine-based First-line Antiretroviral Therapy for Women of Reproductive Potential Living With HIV","status":"COMPLETED","sponsor":"Professor Francois Venter","startDate":"2021-01-04","conditions":"HIV-1-infection","enrollment":133},{"nctId":"NCT05457530","phase":"PHASE3","title":"Doravirine and Weight Gain in Antiretroviral Naive","status":"WITHDRAWN","sponsor":"Prism Health North Texas","startDate":"2022-08-01","conditions":"Body Weight Changes, Human Immunodeficiency Virus, ART","enrollment":""},{"nctId":"NCT03272347","phase":"PHASE2","title":"Islatravir (MK-8591) With Doravirine and Lamivudine in Participants Infected With Human Immunodeficiency Virus Type 1 (MK-8591-011)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2017-11-27","conditions":"HIV-1 Infection","enrollment":123},{"nctId":"NCT03332095","phase":"PHASE1, PHASE2","title":"Evaluating the Pharmacokinetics, Safety, and Tolerability of Doravirine (MK-1439) and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (MK-1439A) in HIV-1-Infected Children and Adolescents","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2018-07-02","conditions":"HIV Infections","enrollment":55},{"nctId":"NCT04429152","phase":"PHASE3","title":"ADORE: Efficacy of DORavirine in Adults Living With HIV Experiencing Virological Failure on First-line Efavirenz-based Antiretroviral Therapy With NNRTI Resistance","status":"UNKNOWN","sponsor":"Professor Francois Venter","startDate":"2021-02-09","conditions":"HIV-1-infection","enrollment":25},{"nctId":"NCT05322083","phase":"","title":"HIV A6 Genome In ART Unsuccessful Patients On DOR","status":"UNKNOWN","sponsor":"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation","startDate":"2022-05","conditions":"Virus-HIV","enrollment":60},{"nctId":"NCT02629822","phase":"PHASE2","title":"Safety and Efficacy of Doravirine, Tenofovir, Lamivudine (MK-1439A) in Participants Infected With Treatment-Naïve Human Immunodeficiency Virus (HIV) -1 With Transmitted Resistance (MK-1439A-030)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2016-01-14","conditions":"HIV-1 Infection","enrollment":10},{"nctId":"NCT03631732","phase":"PHASE3","title":"Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2018-08-28","conditions":"HIV-1 Infection","enrollment":496},{"nctId":"NCT03886701","phase":"PHASE1","title":"Doravirine, Rifapentine and Isoniazid Interaction","status":"COMPLETED","sponsor":"Walter K. Kraft","startDate":"2019-04-22","conditions":"Latent Tuberculosis, Human Immunodeficiency Virus, Rifamycins Causing Adverse Effects in Therapeutic Use","enrollment":11}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":110,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Pifeltro","MK-1439"],"phase":"marketed","status":"active","brandName":"Doravirine (DOR)","genericName":"Doravirine (DOR)","companyName":"Walter K. Kraft","companyId":"walter-k-kraft","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Doravirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that blocks HIV reverse transcriptase to prevent viral replication. Used for HIV-1 infection in treatment-naïve and treatment-experienced adults (in combination antiretroviral therapy).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}